12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revestive regulatory update

Nycomed submitted an MAA to EMA for once-daily subcutaneous Revestive teduglutide to treat short bowel syndrome. The submission triggers a mid-seven-digit milestone payment to NPS,...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >